ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

Block, Committee Agree; No New PDQ For General Public

January 11, 1985

Cancer Center Directors to Develop Blueprint for Progress That’s “Honest,” M.D. Anderson’s John Mendelsohn Says.

November 22, 2006

Vectibix Non-Inferior to Erbitux In Wild-Type Metastatic Disease

October 25, 2013

NCAB Approves, NCI Accepts Powers’ Version Of Board’s Organ Systems Recommendations

May 27, 1983

NIH Panel Calls For More Attention to Cancer Pain

July 26, 2002

Obey Insists NCI Pressured IARC Into Softening Report On Benzene Risk

August 20, 1982